The use of bevacizumab profile in the treatment of cancer patients

• Autores: Juan Francisco Marín Pozo, Almudena Alcalá Sanz, Isabel Caba Porras, Laura Marín Caba, Ana Acuña Vega
• Localización: European journal of clinical pharmacy: atención farmacéutica, ISSN 2385-409X, Vol. 15, Nº. 4, 2013, págs. 255-260
• Idioma: inglés
• Texto completo no disponible (Saber más ...)
• Resumen

  • Objective: To assess and analyze the use of bevacizumab profile at an oncological hospital during from the period of December 2005 until March 2012. Method: A Retrospective observational collecting the following data: diagnosis, dosage, age, line of therapy, date of start and duration of the treatment. We determined the frequencies, mean and medians according to the variable and assessed the degree of adequacy to label. We performed the Kaplan-Meier analysis to measure the duration of therapy variable. Results: We collected data from 228 patients with a mean of 56.5 years of age diagnosed with colorectal cancer (97), breast (47), lung (33), glioblastoma (18), ovarian (15) and others (12). We administered an average of 11 infusions with a mean dose of 644 mg per cycle. The degree of adequacy to label was 65%. The mean duration of therapy was 39.1 weeks (CI 95%: 32.5-45.8), and the median was 24.6 weeks (CI 95%: 19.6-29.6), obtaining similar values in the detailed analysis. Conclusions: Bevacizumab use has similar adequacy to label as those issued for other drugs. The mean duration of therapy was significantly higher than the median, specifying a group of patients who obtained greater benefit than most patients regardless of diagnosis, age and line of therapy